Bristol Myers Squibb (NYSE:BMY) Stock Price Expected to Rise, Rothschild & Co Redburn Analyst Says

Bristol Myers Squibb (NYSE:BMY) had its price objective upped by equities researchers at Rothschild & Co Redburn from $51.00 to $53.00 in a research report issued on Thursday. The firm presently has a “neutral” rating on the biopharmaceutical company’s stock. Rothschild & Co Redburn’s price target points to a potential downside of 10.45% from the stock’s previous close.

Several other brokerages have also weighed in on BMY. JPMorgan Chase & Co. upped their target price on Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Wells Fargo & Company set a $65.00 price objective on shares of Bristol Myers Squibb and gave the stock an “equal weight” rating in a research note on Friday, July 31st. HSBC reiterated a “hold” rating and issued a $65.00 price objective (up from $60.00) on shares of Bristol Myers Squibb in a research note on Thursday, September 10th. Citigroup restated a “neutral” rating and issued a $70.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, August 3rd. Finally, Weiss Ratings upgraded shares of Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $64.96.

Bristol Myers Squibb Trading Down 0.7%

Shares of Bristol Myers Squibb stock traded down $0.40 on Thursday, reaching $59.18. 6,207,278 shares of the company were exchanged, compared to its average volume of 11,985,270. Bristol Myers Squibb has a fifty-two week low of $42.52 and a fifty-two week high of $68.64. The firm has a market capitalization of $120.89 billion, a price-to-earnings ratio of 13.04, a price-to-earnings-growth ratio of 0.28 and a beta of 0.19. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The stock has a fifty day moving average price of $64.27 and a 200-day moving average price of $60.28.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company’s revenue was up 5.7% on a year-over-year basis. During the same quarter last year, the business posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, analysts expect that Bristol Myers Squibb will post 6.95 EPS for the current year.

Insider Transactions at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.05% of the company’s stock.

Hedge Funds Weigh In On Bristol Myers Squibb

Several institutional investors have recently modified their holdings of BMY. BlackRock Inc. lifted its stake in Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after acquiring an additional 8,702,106 shares in the last quarter. State Street Corp raised its stake in shares of Bristol Myers Squibb by 7.3% during the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock worth $6,093,755,000 after purchasing an additional 7,192,724 shares in the last quarter. Primecap Management Co. CA bought a new position in shares of Bristol Myers Squibb in the second quarter valued at $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Bristol Myers Squibb by 0.5% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company’s stock worth $1,315,984,000 after acquiring an additional 119,690 shares in the last quarter. Finally, Independent Franchise Partners LLP increased its stake in shares of Bristol Myers Squibb by 1.0% during the 4th quarter. Independent Franchise Partners LLP now owns 20,828,148 shares of the biopharmaceutical company’s stock worth $1,123,470,000 after purchasing an additional 204,797 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase 3 Zenbexus data: Bristol Myers reported that Zenbexus (iberdomide), combined with daratumumab and dexamethasone, delivered superior progression-free survival versus standard of care in relapsed or refractory multiple myeloma. The EXCALIBER-RRMM results reportedly reduced the risk of progression or death by 51% and produced high minimal residual disease-negative complete response rates, supporting the potential for accelerated approval and future revenue growth. What Could Bristol Myers Squibb Phase 3 Myeloma Data Mean For Investors?
• Positive Sentiment: Pipeline and commercial support: Coverage highlights Zenbexus as a potential growth driver, while Reblozyl’s expanding sales and additional indications may help offset declines from older products. Investors are also attracted to BMY’s profitability, relatively low valuation and high dividend yield. High-Yield Stocks to Buy in October
• Neutral Sentiment: Analyst opinions are mixed: J.P. Morgan issued a Buy rating, while Scotiabank maintained a Hold rating. The split suggests that Zenbexus’s clinical progress is encouraging, but investors remain cautious about execution, competition and the company’s longer-term growth outlook. J.P. Morgan Buy Rating
• Negative Sentiment: Price-target cuts weigh on sentiment: Morgan Stanley assigned a Sell rating, and Cantor Fitzgerald lowered its price target from $59 to $53 while keeping a Neutral rating. These calls indicate concern that the positive pipeline news may already be reflected in the stock or may not fully offset product concentration and competitive risks. Morgan Stanley Sell Rating

Bristol Myers Squibb Company Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.